Australia reimburses deferred medicines
This article was originally published in Scrip
Executive Summary
Australia's health ministry has listed six of the eight drugs deferred for listing on the state-funded Pharmaceutical Benefits Scheme (PBS). The government has also promised not to defer drugs that would cost the system less than A$10 million a year. The R&D-based pharmaceutical association, Medicines Australia, has welcomed the developments, but says more must be done to deal with the deferrals issue properly.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.